1-(6-Carboxyhexyl)-5β-(3-hydroxy-4-phenyl-1-butenyl)-2-pyrrolidon | 356528-12-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-(6-Carboxyhexyl)-5β-(3-hydroxy-4-phenyl-1-butenyl)-2-pyrrolidon
• 英文别名: 7-[(R)-2-((E)-3-Hydroxy-4-phenyl-but-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid；7-[(2R)-2-[(E)-3-hydroxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid
• CAS: 356528-12-6
• 化学式: C₂₁H₂₉NO₄
• 分子量: 359.466
• InChiKey: UZCVIBSSODXGNY-XIFFAYIDSA-N

物化性质

• 沸点：
  585.8±50.0 °C(Predicted)
• 密度：
  1.190±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氧代-3-苯基丙基膦酸二甲酯 在 sodium hydroxide 、 sodium tetrahydroborate 、 N,N-二异丙基乙胺 、 lithium chloride 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 1-(6-Carboxyhexyl)-5β-(3-hydroxy-4-phenyl-1-butenyl)-2-pyrrolidon
  参考文献：
  名称：

  Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization

  摘要：

  A series of 7-[(5R)-substituted 2-oxo-1-pyrrolidinyl]-heptanoic acids were prepared, their isomeric purity determined, and pharmacologically evaluated. Lactams with affinity for the EP4 receptor displayed agonist behavior. The lower side-chain of the lactam template could be substituted to afford ligands (e.g., 17, 24, 30, 31, and 33) of high potency and greater than 1000-fold affinity for EP4 versus the other EP prostanoid receptors. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.063

文献信息

• COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS
  申请人：Van Epps Dennis E.

  公开号：US20120045420A1

  公开（公告）日：2012-02-23

  The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.

  本规范公开了用于移植组织的组合物和方法，用于治疗个体的软组织疾病。
• METHODS OF TREATING SOFT TISSUE DEFECTS
  申请人：Allergan, Inc.

  公开号：US20140179752A1

  公开（公告）日：2014-06-26

  The specification discloses compositions and methods for treating a soft tissue defect of an individual.

  该规范公开了治疗个体软组织缺陷的组成物和方法。
• Discovery of a potent and selective agonist of the prostaglandin EP4 receptor
  作者：Xavier Billot、Anne Chateauneuf、Nathalie Chauret、Danielle Denis、Gillian Greig、Marie-Claude Mathieu、Kathleen M Metters、Deborah M Slipetz、Robert N Young

  DOI：10.1016/s0960-894x(03)00042-8

  日期：2003.3

  Analogues of PGE(2) wherein the hydroxycyclopentanone ring has been replaced by a lactam have been prepared and evaluated as ligands for the EP4 receptor. An optimized compound (19a) shows high potency and agonist efficacy at the EP4 receptor and is highly selective over the other seven known prostaglandin receptors. (C) 2003 Elsevier Science Ltd. All rights reserved.
• DRUG DELIVERY PLATFORMS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF
  申请人：Jiang Guang-Liang

  公开号：US20110052695A1

  公开（公告）日：2011-03-03

  The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.
• Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
  申请人：JIANG GUANG-LIANG

  公开号：US20110111031A1

  公开（公告）日：2011-05-12

  The present specification provides drug delivery platforms useful for the controlled release of a compound over time in an individual.